Get the Stockscreener App
22.43
1.17%
0.26
After Hours:
22.45
0.02
+0.09%
Pacira Biosciences Inc stock is traded at $22.43, with a volume of 469.36K.
It is up +1.17% in the last 24 hours and down -7.43% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$22.17
Open:
$22.23
24h Volume:
469.36K
Relative Volume:
0.69
Market Cap:
$1.04B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
15.47
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-1.32%
1M Performance:
-7.43%
6M Performance:
-0.09%
1Y Performance:
+10.98%
1-Day Range:
$22.15
$22.95
1-Week Range:
$21.44
$23.14
52-Week Range:
$11.16
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.43 | 1.05B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira BioSciences Inc. Stock Analysis and ForecastMarket-crushing stock picks - jammulinksnews.com
Pacira, JNJ in pact to boost Zilretta availability (PCRX) - Seeking Alpha
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts - The Manila Times
Major Expansion: J&J to Co-Promote Pacira's ZILRETTA Across 7M Annual Knee Injections Market - Stock Titan
What drives Pacira BioSciences Inc. stock priceRapid profit acceleration - jammulinksnews.com
Bank of New York Mellon Corp Decreases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
What analysts say about Pacira BioSciences Inc. stockFree Stock Market Return Analysis - Autocar Professional
Is Pacira BioSciences Inc. a good long term investmentGame-changing capital returns - Autocar Professional
Zacks Research Has Negative Estimate for PCRX Q4 Earnings - Defense World
Teacher Retirement System of Texas Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Further Weakness as Pacira BioSciences (NASDAQ:PCRX) Drops 5.9% This Week, Taking Three-year Losses to 60% - 富途牛牛
Shareholders in Pacira BioSciences (NASDAQ:PCRX) have lost 60%, as stock drops 5.9% this past week - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Pacira BioSciences Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
Pacira BioSciences Investors: Know Your Rights Amid Lawsuit - AInvest
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit - PR Newswire
Principal Financial Group Inc. Increases Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $26.44 - Defense World
Pacira BioSciences announces workforce reduction and facility changes By Investing.com - Investing.com Nigeria
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
What makes Pacira BioSciences Inc. stock price move sharplyFree Real-Time Stock Data - Newser
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement - MSN
Allspring Global Investments Holdings LLC Makes New $277,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences (PCRX) Plunges 3.33% Amid Restructuring - AInvest
Pacira Pharmaceuticals Implements Workforce Reduction for Efficiency - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences announces workforce reduction and facility changes - Investing.com Australia
Pacira stock slips amid layoffs in U.S. (PCRX:NASDAQ) - Seeking Alpha
Pacira BioSciences announces workforce reduction - MarketScreener
GAMMA Investing LLC Increases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira Pharmaceuticals Secures New $300M Credit Facility - The Globe and Mail
Murano (MRNO) targets $500M for Bitcoin Treasury via new SEPA | PCRX SEC FilingForm 8-K - Stock Titan
Where are the Opportunities in (PCRX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira Issues Major Stock Compensation Package: 15,800 Shares Granted to New Executives - Stock Titan
Pacira BioSciences: Equity Incentives Fueling Long-Term Growth in Non-Opioid Pain Management - AInvest
PCRX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacira BioSciences, Inc. - ACCESS Newswire
State of Alaska Department of Revenue Has $635,000 Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Upper Peninsula ABC 10News, Sports, Weather and More from Michigan's Upper Peninsula - FinancialContent
Financial Contrast: Pacira BioSciences (NASDAQ:PCRX) & Antibe Therapeutics (OTCMKTS:ATBPD) - Defense World
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):